EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • September 30th, 2022 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Executive Transition and Separation Agreement (this “Agreement”), is entered into as of the date set forth on the signature page below (the “Execution Date”), by and between Daniel Soland (“you”) and Idera Pharmaceuticals, Inc., a Delaware corporation (together with its wholly owned subsidiaries and affiliates, the “Company”).
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • August 14th, 2023 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Executive Transition and Separation Agreement (the “Agreement”) is made as of May 22, 2023 (the “Effective Date”) by and between Solid Biosciences Inc. (the “Company”) and Dr. Carl Morris (the “Executive”) (together, the “Parties”).
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • September 14th, 2022 • Tabula Rasa HealthCare, Inc. • Services-business services, nec • New Jersey
This Executive Transition and Separation Agreement (this “Agreement”), is entered into as of the date set forth on the signature page below (the “Execution Date”), by and between Dr. Orsula V. Knowlton (“you”) and Tabula Rasa Healthcare, Inc. (together with its wholly owned subsidiaries and affiliates, the “Company”).
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • January 3rd, 2020 • Alliance Data Systems Corp • Services-business services, nec • Texas
This Executive Transition and Separation Agreement (the “Separation Agreement”) is made as of December 20, 2019 by and among Alliance Data Systems Corporation, ADS Alliance Data Systems, Inc. (together, the “Company”) and Melisa A. Miller (“Executive”) (collectively, the “Parties”).
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • September 30th, 2022 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Executive Transition and Separation Agreement (the “Agreement”) is made as of September 29, 2022 (the “Effective Date”) by and between Solid Biosciences Inc. (the “Company”) and Erin Powers Brennan (the “Executive”) (together, the “Parties”).
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • January 19th, 2022 • DoubleVerify Holdings, Inc. • Services-computer programming, data processing, etc.
This EXECUTIVE TRANSITION AND SEPARATION AGREEMENT (the “Agreement”), dated as of January 14, 2022 (the “Effective Date”), is entered into by and among Matthew McLaughlin (“Executive”), DoubleVerify Inc., a Delaware corporation (the “Company”) and solely for purposes of Section 1(e), DoubleVerify Holdings, Inc., a Delaware corporation (“Holdings”, and, together with Executive and the Company, the “Parties”). Any term capitalized but not defined in this Agreement will have the meaning set forth in the Employment Agreement between Executive and the Company, dated as of December 31, 2020 (the “Employment Agreement”).
